GAMRIF-MHRA Programme

In April 2024, the Global Antimicrobial Resistance Innovation Fund (GAMRIF) awarded £1.8M to the MHRA for a three-year programme of work that will derisk and complement investments in innovation accelerators CARB-X, FIND, GARDP, BactiVac, IDRC, and FAILSAFE.

GAMRIF supports early-stage innovative research in underfunded areas of antimicrobial resistance (AMR) research and development for the benefit of people in low- and middle-income countries (LMICs).

GAMRIF works with research organisations, governments, and industry around the world to:

• establish international research partnerships and support research competitions that fund innovation and development of new technologies to tackle AMR
• leverage investment from other partners and donors to support sustainable financing for AMR
• establish global research partnerships using a ‘One Health’ approach
• fund projects that will develop solutions specifically for LMICs

MHRA will form part of the wraparound support offered to innovators in GAMRIF-funded programmes to reduce delays and failures related to regulatory challenges.

We will do this by mapping the innovation landscape to ensure clarity and guidance is available where needed, develop reference materials to validate methodologies used to assure product quality, safety, and efficacy as part of market authorisation applications, identify where MHRA can work with other regulators and publicly-funded bodies and non-profit organisations to ensure timely delivery of safe and effective solutions to patients globally that tackle the AMR crisis across One Health in low and middle income countries (LMICs).